CL2022003548A1 - Tratamiento de la disfunción auricular - Google Patents

Tratamiento de la disfunción auricular

Info

Publication number
CL2022003548A1
CL2022003548A1 CL2022003548A CL2022003548A CL2022003548A1 CL 2022003548 A1 CL2022003548 A1 CL 2022003548A1 CL 2022003548 A CL2022003548 A CL 2022003548A CL 2022003548 A CL2022003548 A CL 2022003548A CL 2022003548 A1 CL2022003548 A1 CL 2022003548A1
Authority
CL
Chile
Prior art keywords
treatment
atrial dysfunction
atrial
dysfunction
patient
Prior art date
Application number
CL2022003548A
Other languages
English (en)
Spanish (es)
Inventor
Patrick Henze Marcus
Tamby Jean-Francois
M Edelberg Jay
Howard Takeo Kurio Gregory
Lyle Kelly Cynthia
Yang Chun
L Del Rio Carlos
Lee Anderson Robert
P Sumandea Marius
Ganju Jitendra
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of CL2022003548A1 publication Critical patent/CL2022003548A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2022003548A 2020-06-15 2022-12-13 Tratamiento de la disfunción auricular CL2022003548A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063039438P 2020-06-15 2020-06-15
US202063042512P 2020-06-22 2020-06-22

Publications (1)

Publication Number Publication Date
CL2022003548A1 true CL2022003548A1 (es) 2023-06-09

Family

ID=76845320

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003548A CL2022003548A1 (es) 2020-06-15 2022-12-13 Tratamiento de la disfunción auricular

Country Status (13)

Country Link
US (1) US20230233545A1 (cg-RX-API-DMAC7.html)
EP (1) EP4164644A1 (cg-RX-API-DMAC7.html)
JP (2) JP7832128B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230024977A (cg-RX-API-DMAC7.html)
CN (1) CN116056703A (cg-RX-API-DMAC7.html)
AU (1) AU2021293817A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025551A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180943A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003548A1 (cg-RX-API-DMAC7.html)
IL (1) IL298885A (cg-RX-API-DMAC7.html)
MX (1) MX2022015488A (cg-RX-API-DMAC7.html)
TW (1) TW202214241A (cg-RX-API-DMAC7.html)
WO (1) WO2021257456A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759640B2 (en) * 2022-01-07 2023-09-19 Xyra, Llc Methods for reducing the risk of strokes by pharmacotherapy to reduce the number and duration of atrial fibrillations
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
CN117815534A (zh) * 2023-12-12 2024-04-05 苏州晟智医疗科技有限公司 反搏辅助装置、计算设备、存储介质及反搏系统
CN119157623A (zh) * 2023-12-12 2024-12-20 成都迈格因科技有限公司 一种经导管心脏射频消融的蒸汽爆破安全预警和控制系统
CN118304374A (zh) * 2024-04-01 2024-07-09 山东省中医药研究院附属医院 一种组合物在制备治疗心动过速和/或瓣膜反流药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201705928XA (en) * 2015-01-22 2017-08-30 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
US10758525B2 (en) * 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
CA3060702A1 (en) * 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
JP2020526483A (ja) * 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
SG11202112723PA (en) * 2019-05-19 2021-12-30 Myokardia Inc Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide

Also Published As

Publication number Publication date
AU2021293817A1 (en) 2023-01-19
JP2026048841A (ja) 2026-03-17
WO2021257456A1 (en) 2021-12-23
JP7832128B2 (ja) 2026-03-17
TW202214241A (zh) 2022-04-16
EP4164644A1 (en) 2023-04-19
CN116056703A (zh) 2023-05-02
KR20230024977A (ko) 2023-02-21
US20230233545A1 (en) 2023-07-27
BR112022025551A2 (pt) 2023-03-07
MX2022015488A (es) 2023-03-21
IL298885A (en) 2023-02-01
CA3180943A1 (en) 2021-12-23
JP2023529502A (ja) 2023-07-10

Similar Documents

Publication Publication Date Title
BR112022025551A2 (pt) Tratamento de disfunção atrial
CL2021003045A1 (es) Tratamiento de la disfunción sistólica
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
CO2020005116A2 (es) Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr
CO2020008988A2 (es) Oligonucleótidos antisentido para alfa-sinucleína y usos de los mismos
PE20180260A1 (es) Metodos y kits para tratar la depresion
AR128107A1 (es) Anilinas de 2-pirazol y análogos relacionados para inhibir yap / taz-tead
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2019008085A (es) Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros.
CO2021002691A2 (es) Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1)
MX2015012176A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
MX2017016347A (es) Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal.
CL2021000329A1 (es) Compuestos útiles en terapia del vih
MX362098B (es) El uso de células derivadas de tejido del cordón umbilical y kits que contienen las mismas para el tratamiento de enfermedad vascular periférica.
CL2023000943A1 (es) Formas cristalinas de un compuesto farmacéutico.
CR20160316A (es) Compuestos derivados de hidroxiformamida y usos del mismo
MX2019009418A (es) Formulaciones de combinacion del triplete y metodos para tratar o reducir el riesgo de enfermedad cardiovascular.
ECSP21071644A (es) Compuestos macrocíclicos como agonistas de sting
CL2019002313A1 (es) Combinación de cotinina y antioxidante para la resistencia al tratamiento de la depresión y corrección del déficit funcional de los astrocitos inducido por la depresión y otras afecciones neuropatológicas.
DOP2014000046A (es) COMPOSICIONES Y MÉTODOS PARA TRATAR EL CÁNCER USANDO EL INHIBIDOR DE PI3Kbeta Y EL INHIBIDOR DE LA VÍA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
CO2019014592A2 (es) Neurotoxina botulínica para el tratamiento de trastornos asociados a la hiperactividad de melanocito y/o exceso de melanina
MX2019007555A (es) Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional.
MX2024007929A (es) Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead.
MX2017005499A (es) Composiciones de ester de forbol y metodos de uso para tratar o reducir la duracion de la citopenia.
BR112017025189A2 (en) composition and uses thereof